Display options
Cite
Worndl E, Fung K, Fischer HD, et al. Preventable Diabetic Complications After a Cancer Diagnosis in Patients With Diabetes: A Population-Based Cohort Study. JNCI Cancer Spectr. 2018;2(1):pky008doi: 10.1093/jncics/pky008.
Worndl, E., Fung, K., Fischer, H. D., Austin, P. C., Krzyzanowska, M. K., & Lipscombe, L. L. (2018). Preventable Diabetic Complications After a Cancer Diagnosis in Patients With Diabetes: A Population-Based Cohort Study. JNCI cancer spectrum, 2(1), pky008. https://doi.org/10.1093/jncics/pky008
Worndl, Erin, et al. "Preventable Diabetic Complications After a Cancer Diagnosis in Patients With Diabetes: A Population-Based Cohort Study." JNCI cancer spectrum vol. 2,1 (2018): pky008. doi: https://doi.org/10.1093/jncics/pky008
Worndl E, Fung K, Fischer HD, Austin PC, Krzyzanowska MK, Lipscombe LL. Preventable Diabetic Complications After a Cancer Diagnosis in Patients With Diabetes: A Population-Based Cohort Study. JNCI Cancer Spectr. 2018 Jan;2(1):pky008. doi: 10.1093/jncics/pky008. Epub 2018 May 11. PMID: 29795802; PMCID: PMC5954615.
Copy Download .nbib Format: NLM
Share it on

JNCI Cancer Spectr. 2018 Jan;2(1):pky008. doi: 10.1093/jncics/pky008. Epub 2018 May 11.

Preventable Diabetic Complications After a Cancer Diagnosis in Patients With Diabetes: A Population-Based Cohort Study.

JNCI cancer spectrum

Erin Worndl, Kinwah Fung, Hadas D Fischer, Peter C Austin, Monika K Krzyzanowska, Lorraine L Lipscombe

Affiliations

  1. Department of Medicine, University of Toronto, Toronto, ON, Canada.
  2. Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, ON, Canada.
  3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
  4. Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.
  5. Department of Medicine, Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.

PMID: 29795802 PMCID: PMC5954615 DOI: 10.1093/jncics/pky008

Abstract

BACKGROUND: A cancer diagnosis may disrupt diabetes management, increasing the risk of preventable complications. The objective was to determine whether a cancer diagnosis in patients with diabetes is associated with an increased risk of diabetic complications.

METHODS: This retrospective cohort study using health care data from Ontario, Canada, included persons age 50 years or older diagnosed with diabetes from 2007 to 2011 and followed until 2014. We examined the effects of cancer as a time-varying covariate: breast cancer (in women), prostate cancer (in men), colorectal cancer, and other cancers (in men and women). Each cancer exposure was categorized as stage I-III, IV, or unknown, and by time since cancer diagnosis (0-1 year, >1-3 years, and >3 years). The primary outcome was hospital visits for diabetic emergencies. Secondary outcomes were hospital visits for skin and soft tissue infections and cardiovascular events.

RESULTS: Of 817 060 patients with diabetes (mean age = 64.9 +/- 10.7 years), there were 9759 (1.2%) colorectal and 45 705 (5.6%) other cancers, 6714 (1.7%) breast cancers among 384 257 women and 10 331 (2.4%) prostate cancers among 432 803 men. For all cancers except stage I-III prostate cancer, rates of diabetic complications were significantly higher zero years to one year after diagnosis compared with no cancer (adjusted relative rates ranging from 1.26, 95% confidence interval [CI] = 1.08 to 1.49, to 4.07, 95% CI = 3.80 to 4.36); these differences were attenuated in the subsequent periods after cancer diagnosis.

CONCLUSIONS: Patients with diabetes are at increased risk for preventable complications after a cancer diagnosis. Better diabetes care is needed during this vulnerable period.

References

  1. Cancer. 2007 Jun 15;109(12):2410-9 - PubMed
  2. Clin Sci (Lond). 2009 Nov 23;118(5):315-32 - PubMed
  3. J Clin Oncol. 2011 Jan 1;29(1):40-6 - PubMed
  4. Acta Oncol. 2016 Jun;55(6):720-7 - PubMed
  5. Diabetes Care. 2003 Nov;26(11):3129-35 - PubMed
  6. N Engl J Med. 2012 Apr 5;366(14):1310-8 - PubMed
  7. Diabet Med. 2012 Sep;29(9):1134-41 - PubMed
  8. Diabetes Care. 2009 Jul;32(7):1335-43 - PubMed
  9. Eur Urol. 2013 Jan;63(1):101-7 - PubMed
  10. J Oncol Pract. 2015 Nov;11(6):429-34 - PubMed
  11. J Clin Oncol. 2002 Jan 1;20(1):42-51 - PubMed
  12. Can Fam Physician. 2016 Oct;62(10 ):e589-e598 - PubMed
  13. Cancer. 2004 Oct 15;101(8):1712-9 - PubMed
  14. Ann Surg. 2008 Oct;248(4):585-91 - PubMed
  15. Eur J Endocrinol. 2014 Feb 01;170(2):R43-55 - PubMed
  16. J Cancer Surviv. 2017 Oct;11(5):604-613 - PubMed
  17. Diabetes Care. 2002 Mar;25(3):512-6 - PubMed
  18. Diabetologia. 2015 May;58(5):951-60 - PubMed
  19. J Cancer Surviv. 2010 Dec;4(4):381-7 - PubMed
  20. Med Care. 2007 Sep;45(9):869-75 - PubMed
  21. JAMA. 2008 Dec 17;300(23):2754-64 - PubMed
  22. Ann Transl Med. 2015 Apr;3(5):72 - PubMed
  23. J Surg Res. 2002 Jun 1;105(1):53-7 - PubMed
  24. Am J Clin Oncol. 1997 Aug;20(4):338-41 - PubMed
  25. Diabetes Care. 2010 Apr;33(4):931-9 - PubMed
  26. Breast Cancer Res Treat. 2015 Apr;150(3):613-20 - PubMed
  27. J Clin Epidemiol. 1988;41(5):495-501 - PubMed
  28. Int J Cancer. 2007 May 1;120(9):1986-92 - PubMed
  29. Curr Oncol. 2013 Dec;20(6):e532-8 - PubMed
  30. Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):75-85 - PubMed
  31. Endocr Pract. 2011 Jul-Aug;17(4):616-28 - PubMed
  32. Am J Infect Control. 2008 Apr;36(3):192-8 - PubMed
  33. Anesthesiology. 2009 Feb;110(2):408-21 - PubMed
  34. Diabetes Care. 2007 Jun;30(6):1466-72 - PubMed
  35. Arch Intern Med. 2005 Oct 10;165(18):2090-5 - PubMed

Publication Types